Glecaprevir/Pibrentasvir for the Treatment of PTSD

Completed · Phase 2/Phase 3

Conditions studied: PTSD

In brief

An open-label pilot study to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).

Key facts

Study ID

NCT05446857

Run by

White River Junction Veterans Affairs Medical Center

People needed

10

Starts

2023-04-01

Expected to finish

2024-04-15

Last updated by the study team

2024-08-29

Who can join

Age: 19 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Pregnant or lactating person
• Moderate or severe hepatic impairment (Child-Pugh B or C)
• History of prior hepatic decompensation
• Current use of drugs listed as having significant drug interactions on prescribing label
• Advanced liver disease
• Current or prior hepatitis B infection
• Prior clinical use of GLE/PIB or HCV NS5A inhibitor AND NS3/4A protease inhibitor
• Current HCV infection
• Current psychosis or mania
• Significant suicidal ideation
• Unstable medical conditions
• Current severe alcohol or substance use disorder (excluding nicotine)
• Evidence-based PTSD psychotherapy changes in the past two months
• Evidence-based PTSD medication changes in the past two months

Where it is running

• White River Junction VAMC — White River Junction, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.